Bionik Laboratories Corp.

2023 Q2 Form 10-K Financial Statement

#000141057823001453 Filed on June 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2023

Balance Sheet

Concept 2023 Q2 2023 Q1 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $427.4K $427.4K
YoY Change -78.54% -78.54%
Cash & Equivalents $400.0K $427.4K
Short-Term Investments
Other Short-Term Assets $862.6K $862.6K
YoY Change -23.48% -23.48%
Inventory $1.034M $1.034M
Prepaid Expenses $862.6K
Receivables $453.1K $453.1K
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.778M $2.778M
YoY Change -39.42% -39.42%
LONG-TERM ASSETS
Property, Plant & Equipment $187.7K $442.3K
YoY Change 105.71% 384.84%
Goodwill $99.55K
YoY Change
Intangibles $34.00K
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.694K $8.690K
YoY Change
Total Long-Term Assets $584.6K $584.6K
YoY Change 540.74% 540.69%
TOTAL ASSETS
Total Short-Term Assets $2.778M $2.778M
Total Long-Term Assets $584.6K $584.6K
Total Assets $3.362M $3.362M
YoY Change -28.1% -28.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $557.6K $557.6K
YoY Change 82.77% 82.76%
Accrued Expenses $1.387M $1.409M
YoY Change 58.89% 61.42%
Deferred Revenue $342.4K
YoY Change 9.08%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.309M $2.309M
YoY Change 54.77% 54.77%
LONG-TERM LIABILITIES
Long-Term Debt $2.156M $2.156M
YoY Change
Other Long-Term Liabilities $537.7K $537.7K
YoY Change 109.52% 109.52%
Total Long-Term Liabilities $2.694M $2.694M
YoY Change 949.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.309M $2.309M
Total Long-Term Liabilities $2.694M $2.694M
Total Liabilities $5.003M $5.003M
YoY Change 186.09% 186.09%
SHAREHOLDERS EQUITY
Retained Earnings -$100.3M
YoY Change 5.14%
Common Stock $6.989K
YoY Change 1.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.641M -$1.641M
YoY Change
Total Liabilities & Shareholders Equity $3.362M $3.362M
YoY Change -28.1% -28.1%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2023

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001508381
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Trading Symbol
TradingSymbol
BNKL
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-1340346
CY2023 dei Auditor Name
AuditorName
MNP LLP
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
27094
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
8885
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
27094
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
8885
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
0
CY2023Q1 bnkl Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
64540
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-54717
CY2023 dei Entity Registrant Name
EntityRegistrantName
Bionik Laboratories Corp.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
80 Coolidge Hill Road
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2023 dei City Area Code
CityAreaCode
617
CY2023 dei Local Phone Number
LocalPhoneNumber
926-4800
CY2023 dei Security12b Title
Security12bTitle
N/A
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Public Float
EntityPublicFloat
1374540
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12480431
CY2023 dei Auditor Firm
AuditorFirmId
1930
CY2023 dei Auditor Location
AuditorLocation
Toronto, Canada
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
427383
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1991377
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
453084
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274844
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
862603
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1127362
CY2023Q1 us-gaap Inventory Net
InventoryNet
1034488
CY2022Q1 us-gaap Inventory Net
InventoryNet
1191020
CY2023Q1 us-gaap Assets Current
AssetsCurrent
2777558
CY2022Q1 us-gaap Assets Current
AssetsCurrent
4584603
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
187673
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91234
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8694
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
254650
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
34000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0
CY2023Q1 us-gaap Goodwill
Goodwill
99552
CY2022Q1 us-gaap Goodwill
Goodwill
0
CY2023Q1 us-gaap Assets
Assets
3362127
CY2022Q1 us-gaap Assets
Assets
4675837
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
557610
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
305095
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1387150
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
873030
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22067
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
342354
CY2022Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
313854
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2309181
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1491979
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
234448
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
303292
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
256646
CY2023Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
2155794
CY2022Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2023Q1 us-gaap Liabilities
Liabilities
5002715
CY2022Q1 us-gaap Liabilities
Liabilities
1748625
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6878162
CY2023Q1 bnkl Common Stock Other Shares Issued
CommonStockOtherSharesIssued
111392
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6767114
CY2022Q1 bnkl Common Stock Other Shares Issued
CommonStockOtherSharesIssued
112440
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
6989
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
6879
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98670953
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
98294558
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100348345
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95402321
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
29815
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28096
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1640588
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2927212
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3362127
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4675837
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1805202
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1273712
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
815325
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
320454
CY2023 us-gaap Gross Profit
GrossProfit
989877
CY2022 us-gaap Gross Profit
GrossProfit
953258
CY2023 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1981897
CY2022 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1920749
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
903219
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
998516
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2929800
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2806584
CY2022 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
5200608
CY2023 us-gaap Operating Expenses
OperatingExpenses
5814916
CY2022 us-gaap Operating Expenses
OperatingExpenses
10926457
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-4825039
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-9973199
CY2023 us-gaap Interest Expense
InterestExpense
107150
CY2022 us-gaap Interest Expense
InterestExpense
825209
CY2023 bnkl Other Income Expense
OtherIncomeExpense
-13835
CY2022 bnkl Other Income Expense
OtherIncomeExpense
390414
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-120985
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-434795
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-4946024
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10407994
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.78
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.78
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6903664
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6903664
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5844006
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5844006
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-4946024
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10407994
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1719
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-14053
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1719
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14053
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4944305
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10422047
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
3281030
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
384365
CY2022 bnkl Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
53800
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
642153
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-14053
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-10407994
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2927212
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
308305
CY2023 bnkl Stock Issued During Period Value Issued For Liabilities
StockIssuedDuringPeriodValueIssuedForLiabilities
68200
CY2023 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1719
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-4946024
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-1640588
CY2023 us-gaap Profit Loss
ProfitLoss
-4946024
CY2022 us-gaap Profit Loss
ProfitLoss
-10407994
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63167
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
102623
CY2023 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-105794
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-822568
CY2023 bnkl Common Shares Issued For Investor Relation Expenses
CommonSharesIssuedForInvestorRelationExpenses
68200
CY2022 bnkl Common Shares Issued For Investor Relation Expenses
CommonSharesIssuedForInvestorRelationExpenses
53800
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
459912
CY2023 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2022 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
5200608
CY2023 bnkl Write Off Of Demonstration Equipment
WriteOffOfDemonstrationEquipment
0
CY2022 bnkl Write Off Of Demonstration Equipment
WriteOffOfDemonstrationEquipment
16248
CY2023 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
308305
CY2022 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
384365
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
178240
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-177062
CY2023 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-263953
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-553266
CY2023 bnkl Increase Decrease In Operating Lease
IncreaseDecreaseInOperatingLease
1863
CY2022 bnkl Increase Decrease In Operating Lease
IncreaseDecreaseInOperatingLease
0
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-78373
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
543957
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
262238
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-148960
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
509912
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
104495
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
75145
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1499
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3387314
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4147287
CY2023 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
215000
CY2022 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
CY2023 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
0
CY2022 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
12500
CY2023 bnkl Payments To Acquire Other Non Current Assets
PaymentsToAcquireOtherNonCurrentAssets
8694
CY2022 bnkl Payments To Acquire Other Non Current Assets
PaymentsToAcquireOtherNonCurrentAssets
0
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-223694
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12500
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2050000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
5550000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2050000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5550000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2986
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-7184
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1563994
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1383029
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1991377
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
608348
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
427383
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1991377
CY2023 bnkl Subsidiary Purchase Of Fixed Assets
SubsidiaryPurchaseOfFixedAssets
50185
CY2022 bnkl Subsidiary Purchase Of Fixed Assets
SubsidiaryPurchaseOfFixedAssets
0
CY2023 bnkl Conversion Of Term Loans Into Option Exercises
ConversionOfTermLoansIntoOptionExercises
0
CY2022 bnkl Conversion Of Term Loans Into Option Exercises
ConversionOfTermLoansIntoOptionExercises
642153
CY2023 bnkl Transfer Of Demonstration Equipment From Inventory To Fixed Assets
TransferOfDemonstrationEquipmentFromInventoryToFixedAssets
0
CY2022 bnkl Transfer Of Demonstration Equipment From Inventory To Fixed Assets
TransferOfDemonstrationEquipmentFromInventoryToFixedAssets
42768
CY2023 bnkl Conversion Of Promissory Notes Into Common Stock
ConversionOfPromissoryNotesIntoCommonStock
0
CY2022 bnkl Conversion Of Promissory Notes Into Common Stock
ConversionOfPromissoryNotesIntoCommonStock
8988011
CY2023 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Bionik Laboratories Corp. (“Bionik” or the “Company”) is a robotics company providing neurological functional recovery solutions to improve the quality of life of millions of people with functional or mobility impairments by combining artificial intelligence, innovative technology and data solutions to help individuals regain mobility, enhance autonomy, and regain self-esteem.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company uses artificial intelligence and machine learning technologies to make rehabilitation methods and processes smarter and more intuitive to deliver greater recovery for patients with neurological or mobility impairments. These technologies allow large amounts of data to be collected and processed in real-time, enabling appropriately challenging and individualized therapy during every treatment session. This is the foundation of the InMotion® therapy. The Company’s rehabilitation therapy robots are built on an artificial intelligence platform, measuring the position, the speed and the acceleration of the patient 200 times per second. The artificial intelligence platform is designed to adapt in real time to the patient’s needs and progress while providing quantifiable feedback of a patient’s progress and performance, in a way that the Company believes a trained clinician cannot.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on this foundational work, the Company has a portfolio of products and solutions focused on upper extremity rehabilitation for stroke and other mobility-impaired individuals, including InMotion robots currently in the market. Additionally, the Company’s software platform, InMotion Connect, which is providing the ability for hospital management to access remotely to management dashboards presenting the utilization data of each of their InMotion robotic devices and their robotic devices productivity. Customized reporting capabilities in the platform focus on facility and organization measurement dashboards to support effective decision making for clinicians and for hospital management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On September 7, 2022, the Company acquired Tower Aquatic, described further below, which is the first step in the Company’s planned national strategic rollout of rehabilitation clinics. The Company intends to rebrand the newly acquired physical therapy clinic as a specialized neuro-recovery center that will showcase and provide continued accessibility to Bionik’s technology and solutions by providing treatment to patients with stroke, brain and spinal cord injuries. The Company plans to acquire a network of neuro recovery centers to provide more patients with access to Bionik’s InMotion systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Currently, the Company receives revenues (a) from the sale of its InMotion robots to customers both in the U.S. and internationally, (b) from the operation of its newly acquired rehabilitation center through insurance reimbursements and patient co-payments, (c) associated with its extended warranties that customers purchase with the sale of InMotion robots as well as from the sale of the InMotion Connect hardware and (d) from the subscription fees associated with the utilization of the InMotion Connect Pulse solution in the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company’s principal executive offices are located at 80 Coolidge Hill Road, Watertown, MA 02472</p>
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.97
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.74
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Management Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition, allowance for doubtful accounts, inventory reserves, impairment analysis of goodwill and intangibles including their useful lives, research and development accruals, deferred tax assets, liabilities and valuation allowances, and fair value of stock options. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company as of March 31, 2023 and through the date of this report filing. On an ongoing basis, management evaluates its estimates and actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these consolidated financial statements.</p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
400000
CY2023Q1 bnkl Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
500000
CY2022Q1 bnkl Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
3100000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-100300000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95400000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4900000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10400000
CY2023 bnkl Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0
CY2022 bnkl Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.40
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4300000
CY2023 bnkl Warranty Term
WarrantyTerm
P1Y
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
300000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
400000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.30
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.05
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0395
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0134
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2023 bnkl Royalty Rate
RoyaltyRate
0.03
CY2022 bnkl Impairment Charges
ImpairmentCharges
900000
CY2022Q1 us-gaap Goodwill Gross
GoodwillGross
4300000
CY2021Q1 us-gaap Goodwill
Goodwill
4282984
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
4282984
CY2023 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
99552
CY2023Q1 us-gaap Goodwill
Goodwill
99552
CY2023Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
5580704
CY2023 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
3997217
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1583487
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
34000
CY2022Q1 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
5580704
CY2022 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
3997217
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1583487
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
100000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
100000
CY2022 bnkl Impairment Charges
ImpairmentCharges
900000
CY2023 bnkl Impairment Charges
ImpairmentCharges
0
CY2023Q1 us-gaap Supplies
Supplies
709503
CY2022Q1 us-gaap Supplies
Supplies
956743
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
68094
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
77553
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
85006
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
93066
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
862603
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1127362
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
846965
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
659292
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
187673
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
689940
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
598706
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
91234
CY2023 us-gaap Depreciation
Depreciation
61000
CY2022 us-gaap Depreciation
Depreciation
40000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
79683
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
164825
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
115992
CY2023Q1 bnkl Accrued Director Fees
AccruedDirectorFees
930834
CY2022Q1 bnkl Accrued Director Fees
AccruedDirectorFees
480672
CY2023Q1 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
15088
CY2022Q1 us-gaap Accrued Liabilities For Commissions Expense And Taxes
AccruedLiabilitiesForCommissionsExpenseAndTaxes
22924
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
104603
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
81100
CY2023Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
27094
CY2022Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
8885
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
144706
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
163457
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1387150
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
873030
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
829907
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1083718
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
204581
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
107302
CY2023Q1 us-gaap Inventory Net
InventoryNet
1034488
CY2022Q1 us-gaap Inventory Net
InventoryNet
1191020
CY2022Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.01
CY2022Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2023 bnkl Share Based Compensation Arrangement By Share Based Payment Award Non Options Expired Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice
25.22
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
400000
CY2022 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
50000
CY2023 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
110000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
885504
CY2023 bnkl Percentage On Shares Issued And Outstanding Common Stock Capital Shares Reserved For Future Issuance
PercentageOnSharesIssuedAndOutstandingCommonStockCapitalSharesReservedForFutureIssuance
0.17
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
224282
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
122367
CY2021Q1 bnkl Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionsExercisedWeightedAverageExercisePrice
19.69
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
42684
CY2022 bnkl Share Based Compensation Arrangement By Share Based Payment Award Non Options Expired Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExpiredWeightedAverageExercisePrice
9.38
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
79683
CY2022Q1 bnkl Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionsExercisedWeightedAverageExercisePrice
25.22
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
400000
CY2023Q1 bnkl Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionsExercisedWeightedAverageExercisePrice
0.40
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
79683
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
42684
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
400000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.40
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P5Y
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
22000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
7000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
36989
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
38202
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
38202
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
38202
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
178274
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
329869
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
73353
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
256516
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2509
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2585
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4946025
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10407994
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1239580
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2690193
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
320920
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
990363
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
77270
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
99348
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
228430
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
99585
CY2022 bnkl Deferred Tax Asset Goodwill Impairment
DeferredTaxAssetGoodwillImpairment
1107039
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
612960
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
393858
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
63320
CY2022Q1 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
63563
CY2023Q1 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
12530
CY2023Q1 bnkl Deferred Tax Liabilities Lease Liability
DeferredTaxLiabilitiesLeaseLiability
65010
CY2023Q1 bnkl Deferred Tax Liabilities Operating Loss Carryforwards Domestic
DeferredTaxLiabilitiesOperatingLossCarryforwardsDomestic
2946130
CY2022Q1 bnkl Deferred Tax Liabilities Operating Loss Carryforwards Domestic
DeferredTaxLiabilitiesOperatingLossCarryforwardsDomestic
2923625
CY2023Q1 bnkl Deferred Tax Liabilities Operating Loss Carryforwards
DeferredTaxLiabilitiesOperatingLossCarryforwards
10685250
CY2022Q1 bnkl Deferred Tax Liabilities Operating Loss Carryforwards
DeferredTaxLiabilitiesOperatingLossCarryforwards
10174122
CY2023Q1 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1455940
CY2022Q1 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1255427
CY2023Q1 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1267480
CY2022Q1 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1395599
CY2023Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
16425300
CY2022Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15812336
CY2023Q1 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
70360
CY2023Q1 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
4040
CY2023Q1 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1780
CY2023Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 bnkl Number Of Customers
NumberOfCustomers
1
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
1753
CY2015Q1 bnkl Loan Received And Repaid
LoanReceivedAndRepaid
200000
CY2015Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200000
CY2023 bnkl Percentage Of Royalty On Sales
PercentageOfRoyaltyOnSales
0.01

Files In Submission

Name View Source Status
0001410578-23-001453-index-headers.html Edgar Link pending
0001410578-23-001453-index.html Edgar Link pending
0001410578-23-001453.txt Edgar Link pending
0001410578-23-001453-xbrl.zip Edgar Link pending
bnkl-20230331.xsd Edgar Link pending
bnkl-20230331x10k.htm Edgar Link pending
bnkl-20230331x10k006.jpg Edgar Link pending
bnkl-20230331x10k007.jpg Edgar Link pending
bnkl-20230331x10k008.jpg Edgar Link pending
bnkl-20230331xex31.htm Edgar Link pending
bnkl-20230331xex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
bnkl-20230331_def.xml Edgar Link unprocessable
bnkl-20230331_cal.xml Edgar Link unprocessable
bnkl-20230331_lab.xml Edgar Link unprocessable
bnkl-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
bnkl-20230331x10k_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending